Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study

Area of Science:

• Neonatal pharmacology
• Pediatric nephrology
• Infectious disease

Background:

• Vancomycin is a critical antibiotic for treating serious Gram-positive bacterial infections in neonates.
• Assessing the safety profile of vancomycin, particularly its potential for nephrotoxicity in this vulnerable population, is essential.

Purpose of the Study:

• To compare the incidence of nephrotoxicity, defined as a doubling of baseline serum creatinine, in newborn infants based on peak vancomycin serum concentrations.
• To investigate potential correlations between concomitant disease states, other drug therapies, and changes in serum creatinine levels in vancomycin recipients.

Main Methods:

• Retrospective analysis of 69 neonates with culture-proven staphylococcal septicemia treated with vancomycin for over 3 days.
• Patients were categorized into two groups based on peak vancomycin serum concentrations: 40 microg/mL (Group B).
• Nephrotoxicity was defined as a doubling of serum creatinine; additional analyses used alternative definitions including any rise to >0.6 mg/dL.

Main Results:

• Six out of 61 infants in Group A experienced a doubling of serum creatinine, while none of the 8 infants in Group B did.
• Only 3 infants (all in Group A) had their serum creatinine double to >0.6 mg/dL; 9 out of 10 infants with any rise to >0.6 mg/dL were in Group A.
• No confounding factors, such as underlying diseases or co-administered nephrotoxic drugs, were significantly associated with increased serum creatinine levels.

Conclusions:

• Vancomycin-associated nephrotoxicity appears to be uncommon in neonates.
• Elevated peak vancomycin serum concentrations (>40 microg/mL) did not correlate with an increased incidence of nephrotoxicity in this study cohort.